Mapi pharma’s finished dosage forms activities are divided into two segments:
- Development of generic, non-infringing and new dosage forms of its APIs’ vertical integration development.
- Development of novel and complex finished dosage forms, either generic with high entry barriers or innovative like new combinations, new delivery patterns, etc.
Mapi pharma has in-house capabilities for developing a vast range of complex formulations, ranging from fast dissolving, controlled release dosage forms (matrix, microencapsulation and more) to Depot systems.
Mapi's novel depot technology platform is based on a unique combination of PLGA biodegradable polymers together with parenterally approved additives which enable precise control on the duration and rate of the drugs releases from these systems. Mapi's depot technology is based on combining copolymers of lactide and glycolide referred to as poly (lactide-co-glycolide) PLGA with approved for injection other exipients. Mapi's solution is combining injection pharmaceutically allowed additives like different salts and polysaccharides together with the biodegradable polymers - PLA/PLGA, and by that creating a platform technology which is flexible, robust and enabling accurate design of the drug rate and release duration from its depot.